-
Issues July, August, and September 2004 were printed as Volume 21. They should read Volume 23.
-
A new, and as of yet unpublished study, has raised increased concern about the relationship between rofecoxib (Vioxx), Mercks blockbuster COX-2 inhibitor, and cardiovascular events. The study, which was presented at a meeting in Bordeaux France, was financed by the FDA in collaboration with Californias HMO giant Kaiser Permanente.
-
-
Elevated serum uric acid is a marker for
cardiovascular mortality.
-
In patients with symptomatic nonerosive reflux disease, intermittent on-demand therapy with the PPI rabeprazole provided good symptom control with tablets taken on average approximately 1 day out of 4.
-
Angiotensin-converting enzyme inhibitors decreased the number of defibrillation attempts needed and reduced hospitalization in patients with atrial fibrillation.
-
12-lead ECG obtained from a healthy, asymptomatic 42-year-old man. How many findings can you identify?
-
The National Cholesterol Education Program, a product of a collaboration of the National Heart, Lung, and Blood Institutes, the American College of Cardiology, and the American Heart Association, has updated its clinical practice guideline on cholesterol management.
-
Annual, or less frequent, surveillance intervals are effective for aneurysms < 45 mm in diameter.
-
The FDA has approved the combination of ezetimibe and simvastatin for the treatment of hypercholesterolemia. This combination product provides different mechanisms of action for lowering cholesterol.
